言語を選択

LILRA4

LILRA4 詳細

英語名	Leukocyte immunoglobulin-like receptor subfamily A member 4	市販薬剤の数	0
治験薬の数	1	ターゲットの別称	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
研究＆開発段階	Phase 2 Clinical

英語名	Leukocyte immunoglobulin-like receptor subfamily A member 4
ターゲットの別称	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
市販薬剤の数	0
治験薬の数	1
研究＆開発段階	Phase 2 Clinical

LILRA4 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
His Tag (2)
マーカー
Unconjugated (2)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
LI4-H5243	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag (MALS verified)
LI4-H52H5	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag

総数量2

LILRA4バックグランド

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.

LILRA4分子の別称

LILRA4,CD85g,ILT7,ILT-7

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Daxdilimab	MEDI-7734; VIB-7734; HZN-7734	Phase 2 Clinical	Horizon Therapeutics PLC, Sbi Biotech Co Ltd	Acute Lung Injury; Alopecia Areata; Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Myositis; Polymyositis; Scleroderma, Systemic; Sjogren's Syndrome	詳細